Related content

Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia

By Anargyrou Konstantinos   Vaiopoulos George   Terpos Evangelos   Tsironi Maria   Konstantopoulos Konstantinos   Samarkos Michael   Meletis John  

Haematologia, Vol. 32, Iss. 2, 2002-06 ,pp. : 169-173

VSP

Access to resources Recommend Favorite

Is it time for 5-azacytidine combinations in high-risk myelodysplastic syndrome patients?

By Park Sophie  

Expert Review of Hematology, Vol. 6, Iss. 1, 2013-02 ,pp. : 39-42

Informa Healthcare

Access to resources Recommend Favorite

Clinical experience with decitabine in North American patients with myelodysplastic syndrome

By Yee Karen   Jabbour Elias   Kantarjian Hagop   Giles Francis  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 18-24

Springer Publishing Company

Access to resources Recommend Favorite

Survivin expression in “low-risk” and “high-risk” myelodysplastic syndromes

By Gianelli Umberto   Fracchiolla Nicola   Cortelezzi Agostino   Pellegrini Caterina   Savi Federica   Moro Alessia   Grimoldi Maria   Deliliers Giorgio   Coggi Guido   Bosari Silvano  

Annals of Hematology, Vol. 86, Iss. 3, 2007-03 ,pp. : 185-189

Springer Publishing Company

Access to resources Recommend Favorite

A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule

By Derbel Olfa   Cannas Giovanna   Le Quoc-Hung   Elhamri Mohamed   Chelghoum Youcef   Nicolas-Virelizier Emmanuelle   Nicolini Franck   Troncy Jacques   Barraco Fiorenza   Michallet Mauricette   Thomas Xavier  

Hematology, Vol. 15, Iss. 3, 2010-06 ,pp. : 125-131

Maney Publishing

Access to resources Recommend Favorite